Cytokinetics, Incorporated
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cytokinetics, Incorporated generated cash of -$414,333,000, which is less than the previous year. Cash used in financing activities reached the amount of $221,317,000 last year. Net change in cash is therefore $46,217,000.
Cash Flow
| 2014 | -44.84M | -4.04M | 48.94M |
|---|---|---|---|
| 2015 | 4.88M | 16.06M | 23.91M |
| 2016 | 36.98M | -52.07M | 16.89M |
| 2017 | -101.75M | -65.82M | 225.91M |
| 2018 | -101.21M | 5.13M | 13.13M |
| 2019 | -90.90M | -74.70M | 159.79M |
| 2020 | 8.94M | -196.51M | 234.12M |
| 2021 | -142.52M | -147.77M | 319.98M |
| 2022 | -299.51M | -262.13M | 516.16M |
| 2023 | -414.33M | 239.25M | 221.31M |
CYTK Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 67.18M | 112.66M | 82.98M | 36.43M | 42.25M | 125.20M | 66.87M | 65.07M | 20.21M | 20.15M |
Operating activities | ||||||||||
Net income | -526.24M | -388.95M | -215.31M | -127.29M | -121.69M | -106.28M | -127.79M | 16.45M | -37.50M | -14.64M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 11.89M | 5.81M | 2.27M | 1.83M | 1.29M | 1.23M | 1.92M | 741K | 589K | 490K |
Stock-based compensation expense | 72.06M | 47.85M | 26.83M | 17.62M | 10.75M | 0 | 9.02M | 7.14M | 4.56M | 3.33M |
| Deferred income tax benefit | 72.06M | 47.85M | 26.83M | 17.62M | 10.75M | 0 | 9.02M | 7.14M | 4.56M | 3.33M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -1.13M | 56.67M | -47.39M | 743K | -2.93M | -1.11M | -1.08M | -12K | 46.63M | -46.64M |
Inventories | 0 | 0 | 0 | 1.48M | -5.35M | 4.90M | -1.39M | 8.23M | 2.59M | -2.59M |
Accounts payable | -3.48M | 4.52M | 1.05M | -110K | 4.39M | -1.49M | 1.45M | 1.69M | 755K | -2.17M |
Cash generated by operating activities | -414.33M | -299.51M | -142.52M | 8.94M | -90.90M | -101.21M | -101.75M | 36.98M | 4.88M | -44.84M |
Investing activities | ||||||||||
Purchases Of Investments | -635.21M | -855.39M | -525.04M | -435.82M | -277.88M | -240.22M | -240.41M | -145.15M | -115.56M | -107.04M |
Investments In Property Plant And Equipment | -1.41M | -11.33M | -48.87M | -11.05M | -2.61M | -889K | -2.87M | -1.59M | -562K | -1.10M |
Acquisitions Net | 0 | 250.79M | 98.90M | 185.46M | 72.08M | 14K | 0 | 33K | 1K | 0 |
Cash generated by investing activities | 239.25M | -262.13M | -147.77M | -196.51M | -74.70M | 5.13M | -65.82M | -52.07M | 16.06M | -4.04M |
Financing activities | ||||||||||
Common Stock Issued | 164.23M | 17.54M | 312.04M | 225.10M | 36.21M | 3.23M | 119.78M | 1.89M | 8.67M | 48.97M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 17.54M | -4.44M | -2.25M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -858K | 334.66M | 0 | 0 | 135.57M | -9.89M | 1.26M | -14.99M | 14.89M | 0 |
Cash used in financing activities | 221.31M | 516.16M | 319.98M | 234.12M | 159.79M | 13.13M | 225.91M | 16.89M | 23.91M | 48.94M |
Net Change In Cash | 46.21M | -45.48M | 29.68M | 46.55M | -5.82M | -82.95M | 58.33M | 1.79M | 44.86M | 57K |
Cash at end of period | 113.39M | 67.18M | 112.66M | 82.98M | 36.43M | 42.25M | 125.20M | 66.87M | 65.07M | 20.21M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |